GlobeNewswire Inc | Oct 14, 2020 05:05PM EDT

October 14, 2020

CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need,today announced that it will present preclinical data from its novel Immunosynthen STING-agonist ADC platform at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place virtually from November 9-14, 2020.

Details of the poster display are as follows:

Poster Title:Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugatesAbstract Number: 620E-poster Available9 a.m. 5 p.m. ET, November 11-14, 2020. Location Virtual Poster Hall

AboutMersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersanas second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersanas customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Contact

Investor& Media ContactSarah Carmody, 617-844-8577scarmody@mersana.com